Neuland Laboratories has announced a board meeting to be held on November 7, 2025, to approve the unaudited financial results for the quarter and half year ended September 30, 2025. The trading window for dealing in the company’s equity shares will remain closed until 48 hours after the declaration of the results. This announcement informs shareholders and investors about the upcoming financial review.
Board Meeting Announcement
Neuland Laboratories has scheduled a meeting of its Board of Directors to be held on November 7, 2025. The primary purpose of this meeting is to review and approve the unaudited financial results (Standalone and Consolidated) for the quarter and half year ended September 30, 2025.
Trading Window Closure
As per the company’s Insider Trading Code, the trading window for dealing in the equity shares of Neuland Laboratories will remain closed. This closure began on October 1, 2025, and will continue until 48 hours after the declaration of the aforementioned unaudited financial results. This measure ensures compliance and prevents insider trading based on unpublished financial information.
Financial Results Review
The upcoming board meeting will focus on assessing the company’s financial performance for Q2 (Jul-Sep) of FY26. The board will review both standalone and consolidated financial statements to provide a comprehensive overview of the company’s financial health.
Source: BSE
